Full text is available at the source.
Psychedelic-assisted therapy: An overview for the internist
An introduction to psychedelic-assisted therapy for general doctors
AI simplified
Abstract
Preliminary evidence suggests that psychedelic-assisted therapy may be efficacious for various mental health conditions.
- Psychedelics such as MDMA and psilocybin are being investigated for their potential benefits in treating depression, posttraumatic stress disorder, and substance use disorders.
- The US Food and Drug Administration (FDA) has designated psilocybin, MDMA, and lysergic acid diethylamide as breakthrough therapies.
- In August 2024, the FDA declined to approve a New Drug Application for MDMA, requesting further phase 3 trials.
- Clinicians are encouraged to prepare for the potential reintroduction of psychedelics into medical practice.
AI simplified